ABOS (Acumen Pharmaceuticals) 1-Year Sharpe Ratio: 1.67 (As of Jul. 08, 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.74
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals 1-Year Sharpe Ratio?

Acumen Pharmaceuticals ABOS +6.64% 34 1-Year Sharpe Ratio is 1.67 as of Jul. 08, 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-08), Acumen Pharmaceuticals's 1-Year Sharpe Ratio is 1.67.

Acumen Pharmaceuticals  (NAS:ABOS) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Acumen Pharmaceuticals 1-Year Sharpe Ratio Related Terms

ABOS vs YDES, PYXS, CRBU: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Acumen Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's 1-Year Sharpe Ratio falls into.


ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.67 mean?
Acumen Pharmaceuticals (ABOS) has a 1-Year Sharpe Ratio of 1.67 as of Jul. 08, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' 1-Year Sharpe Ratio too high?
Acumen Pharmaceuticals' current 1-Year Sharpe Ratio is 1.67. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' 1-Year Sharpe Ratio compare to YDES and PYXS?
Acumen Pharmaceuticals' 1-Year Sharpe Ratio of 1.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current 1-Year Sharpe Ratio is 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current 1-Year Sharpe Ratio of 1.67. The current 1-Year Sharpe Ratio is 1.67. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current 1-Year Sharpe Ratio is 1.67 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price